iiinova — where your digital self keeps evolving

Ziad Bakouny, MD, MSc @ziadbakouny.bsky.social · 21/05/2026

Cool new study in #JCOCCI shows that USPSTF shift in prostate cancer screening recommendations for men age 55–69 years (Grade D → Grade C) was associated with increased screening rates across payer groups in a Colorado all-payer claims database. @jco-asco.bsky.social ascopubs.org/doi/10.1200/...

000

Reposted by Ziad Bakouny, MD, MSc

Hannah R. Abrams @hannahrabrams.bsky.social · 24/03/2026

Should we be reserving stem cells for every patient with #myeloma treated with BCMA CAR T? Reduces severe infections by over half, but >4x cost. Need risk-stratification (or IVIG) to make sustainable. Cost effectiveness modeling in #JCOCCI : ascopubs.org/doi/10.1200/... @ziadbakouny.bsky.social

Title page and abstract:
Cost-Effectiveness of Maintaining Higher Stem-Cell Collection Thresholds in the Chimeric Antigen Receptor T-Cell Era for Multiple Myeloma
Ehsan Malek, MD 1 ; Brian Betts, MD 1 ; Megan Herr, PhD 1 ; Marco Davila, MD 1 ; Shernan Holtan, MD 1 ; James J. Driscoll, MD, PhD 2,3 ; and Han Yu, PhD 1

FIG 3. Cost breakdown by strategy. Stacked bar chart of per-patient costs for the no-boost and boost
strategies. In the no-boost arm, all costs are attributable to hospitalization for infection. In the boost
arm, upfront reserve collection accounts for the majority of costs, while infection-related costs are
markedly lower. Total costs for each strategy represent the sum of upfront collection/storage fees
and longitudinal infection-related hospitalization costs. USD, US dollars.

Figure demonstrates cost per patient >$20,000 in boost group, under $5000 in no boost group. Majority of costs attributable to cost of stem cell collection up-front.

131

Ziad Bakouny, MD, MSc @ziadbakouny.bsky.social · 17/03/2026

A very timely and important special series by #JCOCCI on LLMs in Oncology! Covers everything from current uses to challenges with implementation and ethical concerns. @jco-asco.bsky.social @ascocancer.bsky.social lnkd.in/e6DJYuG8

010

Ziad Bakouny, MD, MSc @ziadbakouny.bsky.social · 08/03/2026

Thanks to this group of reviewers and all the outstanding reviewers @ #JCOCCI. If you're not a reviewer already, consider signing up! Great way to keep up with the field and force yourself to read papers thoroughly. @jco-asco.bsky.social @ascocancer.bsky.social Become a reviewer: bit.ly/40H06RS

010

Ziad Bakouny, MD, MSc @ziadbakouny.bsky.social · 22/04/2025

Really looking forward to #AACR25, my first @theaacr.bsky.social Annual Meeting! Thanks to AACR for inviting me to be a social media ambassador. Please follow along for all the cool science from #AACR25!

140